glp 1 def Potential Use of GLP-1 and GIP/GLP-1 Receptor Agonists for Respiratory Disorders: Where Are We at? The GLP-1 Agonists and Obesity:

Check 6 Does the Provider Have a Verified Reputation and Operational Transparency

Initially approved for diabetes treatment, semaglutide gained recognition for its side effect of weight loss

Education, vigilance, and timely action save lives

Exclusion criteria included patients younger than 18 years, any patient with a death date on or before the index date (deceased patients at baseline), individuals with pre-existing conditions known to impact gastrointestinal GI functions, e.g., major GI or abdominal surgeries, connective tissue disorders (e.g., amyloidosis, Ehlers-Danlos syndrome, Sjgrens syndrome), inflammatory bowel diseases, and other major systemic or GI conditions (cystic fibrosis, intestinal failure, etc.) predisposing to SIBO

Note: After the Food and Drug Administration (FDA) approves a drug, it tracks and reviews side effects of the medication

Early small studies of SGLT2 inhibitors in T1D showed promising results with evidence of decreased total daily insulin dosage, improvement in fasting glucose and A1C, measures of glycemic variability, rates of hypoglycemia and body weight (76-78)